Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Morrison

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
The Journal of Experimental Medicine|April 23, 2025
Microglia and CD8+ T cell activation precede neuronal loss in a murine model of spastic paraplegia 15Aleksej Frolov, Hao Huang, Dagmar Schütz, et al.
Acta Neuropathologica|November 16, 2011
Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meetingMichel Kalamarides, Maria T Acosta, Dusica Babovic-Vuksanovic, et al.
Neuro-Oncology|January 8, 2019
Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance developmentMarisa A Fuse, Christine T Dinh, Jeremie Vitte, et al.
American Journal of Medical Genetics. Part A|April 23, 2018
2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosisMichael J Fisher, Allan J Belzberg, Peter de Blank, et al.
Plos One|June 14, 2018
Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2, Robert Allaway, Steve P Angus, et al.
American Journal of Medical Genetics. Part A|September 27, 2014
Update from the 2013 International Neurofibromatosis ConferenceScott R Plotkin, Anne C Albers, Dusica Babovic-Vuksanovic, et al.
American Journal of Medical Genetics. Part A|January 21, 2014
CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapiesBrigitte C Widemann, Maria T Acosta, Sylvia Ammoun, et al.
Plos One|July 15, 2021
Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALKLong-Sheng Chang, Janet L Oblinger, Abbi E Smith, et al.
Mechanisms of Ageing and Development|May 5, 2026
The need to increase support for healthy ageing and longevity research in the EU by establishing a Coordination and Support Programme on Healthy Ageing and LongevityIlia Stambler, Alexander Tietz-Latza, Björn Schumacher, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
The Journal of Experimental Medicine|April 23, 2025
Microglia and CD8+ T cell activation precede neuronal loss in a murine model of spastic paraplegia 15Aleksej Frolov, Hao Huang, Dagmar Schütz, et al.
Acta Neuropathologica|November 16, 2011
Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meetingMichel Kalamarides, Maria T Acosta, Dusica Babovic-Vuksanovic, et al.
Neuro-Oncology|January 8, 2019
Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance developmentMarisa A Fuse, Christine T Dinh, Jeremie Vitte, et al.
American Journal of Medical Genetics. Part A|April 23, 2018
2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosisMichael J Fisher, Allan J Belzberg, Peter de Blank, et al.
Plos One|June 14, 2018
Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2, Robert Allaway, Steve P Angus, et al.
American Journal of Medical Genetics. Part A|September 27, 2014
Update from the 2013 International Neurofibromatosis ConferenceScott R Plotkin, Anne C Albers, Dusica Babovic-Vuksanovic, et al.
American Journal of Medical Genetics. Part A|January 21, 2014
CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapiesBrigitte C Widemann, Maria T Acosta, Sylvia Ammoun, et al.
Plos One|July 15, 2021
Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALKLong-Sheng Chang, Janet L Oblinger, Abbi E Smith, et al.
Mechanisms of Ageing and Development|May 5, 2026
The need to increase support for healthy ageing and longevity research in the EU by establishing a Coordination and Support Programme on Healthy Ageing and LongevityIlia Stambler, Alexander Tietz-Latza, Björn Schumacher, et al.
Pageof 7